RxDoctor Payments Data

Jennifer Barbosa

Nurse Practitioner · Scottsdale, AZNPI 1770086456

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $16,688 of the $20,573 with a category attached, or 81.1%. It is spread thinly across 60 manufacturers, the largest accounting for just 8.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $5,423 and has fallen 89.3% since, to $578 in 2025. Among nurse practitioner clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$20,573in general payments, 2019–2025

Across 813 payments — averaging $25.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$2K
  • AstraZeneca$2K
  • Novartis$1K
  • Johnson & Johnson$956
  • Pfizer$878
  • Seagen Inc.$869
  • plus $13K from 54 others

What the payments were for

  • Consulting fees$2,07510%
  • Speaking & faculty fees$7003%
  • Food & beverage$16,68881%
  • Education$1,1105%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Daiichi Sankyo Inc.19$1,728
AstraZeneca(2 entities)51$1,715
Novartis59$1,032
Johnson & Johnson(2 entities)32$956
Pfizer46$878
Seagen Inc.32$869
Astellas Pharma US Inc26$812
CTI Biopharma Corp.3$742
Bristol Myers Squibb52$716
Incyte Corporation21$609
Genentech USA, Inc.18$600
E.r. Squibb & Sons, L.L.C.22$518
Gilead(2 entities)21$510
Merck27$500
Sanofi24$462
Rigel Pharmaceuticals, Inc.17$438
Bayer22$425
AbbVie25$415
Amgen25$397
Eisai Inc.21$395
Pharmacyclics LLC, An Abbvie Company20$371
Ipsen Biopharmaceuticals, Inc12$371
AVEO Pharmaceuticals, Inc.11$361
Blueprint Medicines Corporation14$337
GSK13$317
Beigene USA, Inc.10$302
Puma Biotechnology, Inc.11$265
Takeda Pharmaceuticals U.S.A., Inc.9$247
Regeneron Healthcare Solutions, Inc.8$231
Sobi, Inc7$199
Mirati Therapeutics, Inc.10$180
Jazz Pharmaceuticals Inc.7$173
Array Biopharma Inc10$160
EMD Serono, Inc.7$149
Myovant Sciences Inc.8$144
Karyopharm Therapeutics Inc.7$135
Progenics Pharmaceuticals, Inc.1$125
Lilly USA, LLC8$117
Genmab U.S., Inc.1$113
Tersera Therapeutics LLC4$106
Taiho Oncology, Inc.4$104
Adaptive Biotechnologies Corporation5$96
Stemline Therapeutics Inc.5$84
Springworks Therapeutics, Inc.4$77
Servier Pharmaceuticals LLC3$74
Sun Pharmaceutical Industries Inc.3$73
ADC Therapeutics America, Inc.3$72
Dova Pharmaceuticals4$69
Exelixis Inc.3$67
Morphosys, US Inc.4$65
G1 Therapeutics, Inc.3$63
Clovis Oncology, Inc.3$58
Deciphera Pharmaceuticals Inc.3$57
Boehringer Ingelheim2$54
Coherus Oncology, Inc.2$50
Global Blood Therapeutics, Inc.3$44
Organon3$42
Sumitomo Pharma America, Inc.2$40
Chiesi USA, Inc.2$38
Fennec Pharmaceuticals, Inc.1$34

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,573 in reported general payments places this provider in the 95th percentile of 1,719 nurse practitioner providers in Arizona.

See all nurse practitioner providers in Arizona

Medicare billing

Part B allowed, 2024
$46,196
Medicare patients
271
Services billed
909

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban17$14,780
Oxycodone Hcl78$1,231
Morphine Sulfate ErMorphine Sulfate37$1,140
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen17$310
Acyclovir18$303
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen14$280
Gabapentin13$188
Dexamethasone12$89
Potassium Chloride13$82
Prednisone23$81

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$878$14,78017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,719 nurse practitioner providers in Arizona.

Other nurse practitioner in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →